Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/ Computerized Tomography Investigation
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Objective: Dopamine plays a significant role in working memory by acting as a key neuromodulator between brain networks. Additionally, treatment of patients with schizophrenia using amisulpride, a pure dopamine class 2/3 receptor antagonist, improves their clinical symptoms with fewer side effects. We hypothesized that patients with schizophrenia treated with amisulpride and aripiprazole show increased working memory and glucose metabolism compared with those treated with cognitive behavioral therapy (CBT) and aripiprazole instead. Methods: Sixteen patients with schizophrenia (eight in the amisulpride group [aripiprazole+amisulpride] and eight in the CBT group [aripiprazole+CBT]) and 15 age- and sex-matched healthy control subjects were recruited for a 12-week-long prospective trial. An [18F]-fluorodeoxyglucose-positron emission tomography/computerized tomography scanner was used to acquire the images. Results: After 12 weeks of treatment, the amisulpride group showed greater improvement in the Letter-Number Span scores than the CBT group. Additionally, although brain metabolism in the left middle frontal gyrus, left occipital lingual gyrus, and right inferior parietal lobe was increased in all patients with schizophrenia, the amisulpride group exhibited a greater increase in metabolism in both the right superior frontal gyrus and right frontal precentral gyrus than the CBT group. Conclusion: This study suggests that a small dose of amisulpride improves the general psychopathology, working memory performance, and brain glucose metabolism of patients with schizophrenia treated with aripiprazole.
Abstract
Objective: Dopamine plays a significant role in working memory by acting as a key neuromodulator between brain networks. Additionally, treatment of patients with schizophrenia using amisulpride, a pure dopamine class 2/3 receptor antagonist, improves their clinical symptoms with fewer side effects. We hypothesized that patients with schizophrenia treated with amisulpride and aripiprazole show increased working memory and glucose metabolism compared with those treated with cognitive behavioral therapy (CBT) and aripiprazole instead. Methods: Sixteen patients with schizophrenia (eight in the amisulpride group [aripiprazole+amisulpride] and eight in the CBT group [aripiprazole+CBT]) and 15 age- and sex-matched healthy control subjects were recruited for a 12-week-long prospective trial. An [18F]-fluorodeoxyglucose-positron emission tomography/computerized tomography scanner was used to acquire the images. Results: After 12 weeks of treatment, the amisulpride group showed greater improvement in the Letter-Number Span scores than the CBT group. Additionally, although brain metabolism in the left middle frontal gyrus, left occipital lingual gyrus, and right inferior parietal lobe was increased in all patients with schizophrenia, the amisulpride group exhibited a greater increase in metabolism in both the right superior frontal gyrus and right frontal precentral gyrus than the CBT group. Conclusion: This study suggests that a small dose of amisulpride improves the general psychopathology, working memory performance, and brain glucose metabolism of patients with schizophrenia treated with aripiprazole.
참고문헌 (61)
- Conn PJ, "Schizophrenia : moving beyond monoamine antagonists", Mol Interv, 8, pp.99~107 (2008)
- Green MF, "What are the functional consequences of neurocognitive deficits in schizophrenia", Am J Psychiatry, 153, pp.321~330 (1996)
- McGurk SR, "The role of cognition in vocational functioning in schizophrenia", Schizophr Res, 45, pp.175~184 (2000)
- Lesh TA, "Cognitive control deficits in schizophrenia : mechanisms and meaning", Neuropsychopharmacology, 36, pp.316~338 (2011)
- Elvevåg B, "Cognitive impairment in schizophrenia is the core of the disorder", Crit Rev Neurobiol, 14, pp.1~21 (2000)
- Lewis R, "Should cognitive deficit be a diagnostic criterion for schizophrenia", J Psychiatry Neurosci, 29, pp.102~113 (2004)
- Nuechterlein KH, "Identification of separable cognitive factors in schizophrenia", Schizophr Res, 72, pp.29~39 (2004)
- Cammisuli DM, "Cognitive psychopathology in Schizophrenia : comparing memory performances with obsessive-compulsive disorder patients and normal subjects on the Wechsler Memory Scale-IV", Psychiatr Danub, 28, pp.118~126 (2016)
- Hawkins KA, "Memory deficits in patients with schizophrenia : preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings", J Psychiatry Neurosci, 24, pp.341~347 (1999)
- Hawkins KA, "Memory deficits in schizophrenia : inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale--revised", J Psychiatry Neurosci, 22, pp.169~179 (1997)
- Wang CH, "A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia", Schizophr Res, 144, pp.129~135 (2013)
- Brébion G, "Decreased processing speed might account for working memory span deficit in schizophrenia, and might mediate the associations between working memory span and clinical symptoms", Eur Psychiatry, 29, pp.473~478 (2014)
- Lee J, "Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia(COGS)study : the moderating role of smoking status and antipsychotic medications", Schizophr Res, 163, pp.24~31 (2015)
- Horan WP, "Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives : findings from the Consortium on the Genetics of Schizophrenia", Schizophr Res, 103, pp.218~228 (2008)
- Perry W, "Working memory in schizophrenia : transient"online"storage versus executive functioning", Schizophr Bull, 27, pp.157~176 (2001)
- Pukrop R, "Dimensions of working memory dysfunction in schizophrenia", Schizophr Res, 62, pp.259~268 (2003)
- Sawaguchi T, "D1 dopamine receptors in prefrontal cortex : involvement in working memory", Science, 251, pp.947~950 (1991)
- Cools R, "Inverted-U-shaped dopamine actions on human working memory and cognitive control", Biol Psychiatry, 69, pp.e113~e125 (2011)
- Slifstein M, "Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia : a positron emission tomographic functional magnetic resonance imaging study", JAMA Psychiatry, 72, pp.316~324 (2015)
- Kim DI, "Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study", Hum Brain Mapp, 30, pp.3795~3811 (2009)
- Meda SA, "Evidence for anomalous network connectivity during working memory encoding in schizophrenia: an ICA based analysis", PLoS One, 4, pp.e7911~ (2009)
- Rasetti R, "Altered cortical network dynamics : a potential intermediate phenotype for schizophrenia and association with ZNF804A", Arch Gen Psychiatry, 68, pp.1207~1217 (2011)
- Chang C, "Temporal dynamics of basal ganglia response and connectivity during verbal working memory", Neuroimage, 34, pp.1253~1269 (2007)
- Moore AB, "Bilateral basal ganglia activity in verbal working memory", Brain Lang, 125, pp.316~323 (2013)
- McNab F, "Prefrontal cortex and basal ganglia control access to working memory", Nat Neurosci, 11, pp.103~107 (2008)
- Geiger LS, "Novelty modulates human striatal activation and prefrontal-striatal effective connectivity during working memory encoding", Brain Struct Funct, 223, pp.3121~3132 (2018)
- Fusar-Poli P, "Abnormal frontostriatal interactions in people with prodromal signs of psychosis : a multimodal imaging study", Arch Gen Psychiatry, 67, pp.683~691 (2010)
- Quidé Y, "Task-related fronto-striatal functional connectivity during working memory performance in schizophrenia", Schizophr Res, 150, pp.468~475 (2013)
- Efficacy and safety of first-generation and second-generation anti-psychotic drugs for schizophrenia in adults: an overview of systematic reviews, "Pike E", Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH), ~, pp.Report No.: 08-2009 (2009)
- Vasan S, "Atypical antipsychotic agents" (2018), StatPearls Publishing
- Schöll M, "Fluorodeoxyglucose PET in neurology and psychiatry", PET Clin, 9, pp.371~390 (2014)
- Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- Kasper Jessen, "Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D2", 3 receptor antagonist treatment, 2019, pp.49(5), 754~763[DOI]
- Mitelman SA, "Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia", Brain Imaging Behav, 12, pp.532~546 (2018)
- Buchsbaum MS, "Positron emission tomography studies of abnormal glucose metabolism in schizophrenia", Schizophr Bull, 24, pp.343~364 (1998)
- Soares JC, "Neurochemical brain imaging investigations of schizophrenia", Biol Psychiatry, 46, pp.600~615 (1999)
- Fujimoto T, "Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia", Psychiatry Res, 154, pp.49~58 (2007)
- Park HJ, "Cortical surface-based analysis of 18F-FDG PET : measured metabolic abnormalities in schizophrenia are affected by cortical structural abnormalities", Neuroimage, 31, pp.1434~1344 (2006)
- Fernandez-Egea E, "18FDG PET study of amygdalar activity during facial emotion recognition in schizophrenia", Eur Arch Psychiatry Clin Neurosci, 260, pp.69~76 (2010)
- Epstein J, "Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies", Ann N Y Acad Sci, 877, pp.562~574 (1999)
- Holcomb HH, "Functional sites of neuroleptic drug action in the human brain : PET", FDG studies with and without haloperidol, 1996, pp.153, 41~49
- Duarte JMN, "Magnetic resonance spectroscopy in schizophrenia : evidence for glutamatergic dysfunction and impaired energy metabolism", Neurochem Res, 44, pp.102~116 (2019)
- Keller SS, "Comparison of standard and optimized voxel-based morphometry for analysis of brain changes associated with temporal lobe epilepsy", Neuroimage, 23, pp.860~868 (2004)
- Nowinski WL, "The cerefy brain atlases : continuous enhancement of the electronic talairach-tournoux brain atlas", Neuroinformatics, 3, pp.293~300 (2005)
- Choudhary M, "F-18 fluorodeoxyglucose positron emission tomography study of impaired emotion processing in first episode schizophrenia", Schizophr Res, 162, pp.103~107 (2015)
- Meltzer HY, "New trends in the treatment of schizophrenia", CNS Neurol Disord Drug Targets, 16, pp.900~906 (2017)
- Zhu Y, "Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia : a systematic review with pairwise and network meta-analyses", Lancet Psychiatry, 4, pp.694~705 (2017)
- Khanna P, "Aripiprazole versus other atypical antipsychotics for schizophrenia", Cochrane Database Syst Rev, (1), pp.CD006569~ (2014)
- Leucht S, "Amisulpride, an unusual"atypical"antipsychotic : a meta-analysis of randomized controlled trials", Am J Psychiatry, 159, pp.180~190 (2002)
- Tyson PJ, "Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors", Int J Neurosci, 114, pp.593~611 (2004)
- Wagner M, "Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism : randomized controlled trial of olanzapine vs amisulpride", Neuropsychopharmacology, 30, pp.381~390 (2005)
- Topolov MK, "Cognitive impairment in schizophrenia, neurotransmitters and the new atypical antipsychotic aripiprazole", Folia Med(Plovdiv), 58, pp.12~18 (2016)
- Suzuki H, "Influence of aripiprazole once monthly on clinical symptoms and cognitive function in two schizophrenia patients : preliminary results", Psychiatry Clin Neurosci, 70, pp.71~72 (2016)
- Shigenori Tadokoro, "Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report", Clinical Psychopharmacology and Neuroscience, 15(1), pp.79~81 (2017), 대한정신약물학회[DOI]
- Keefe RS, "The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia : a review and meta-analysis", Schizophr Bull, 25, pp.201~222 (1999)
- -raclopride PET study with aripiprazole, "Transl Psychiatry", 2018, 87~
- Davidson M, "Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder : a randomized, open-label clinical trial(EUFEST)", Am J Psychiatry, 166, pp.675~682 (2009)
- Mortimer AM, "Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia", Hum Psychopharmacol, 22, pp.445~454 (2007)
- Green MF, "Neurocognitive deficits and functional outcome in schizophrenia : are we measuring the"right stuff"", Schizophr Bull, 26, pp.119~136 (2000)
- Swartz BE, "An 18FDG-PET study of cortical activation during a short-term visual memory task in humans", Neuroreport, 5, pp.925~928 (1994)
- Molina V, "Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia", Psychiatry Res, 173, pp.88~93 (2009)
